The Official CORMEDIX (CRMD)thread (run up to FDA approval has begun )

[KING WILL]

More on profit margin and business model as I understand it so far:


For comparison, Apples profit margin is about 38%. NexTech has a very sustainable profit margin.

And part of their business model is more, or less an subscription service that allows them do insert a line of code 1 time and charge $30(SKU) per month for that. And companies that sign deals with them will have multiple products they are paying for.

For more comparison, Nextflix has 150m subscribers charging around $15 per month, but the overhead is so high. Cloud space and making movies isnt cheap. So, Netflix brings in $3.3B in revenue, but only profits $186m.

For one last comparison, I'm using Amazon. Amazon profit margins is only 3.8%....

60% vs 38% vs 3.8%

Now, here is where its gets interesting imo. The cheapest offering (SKU) is between $20-$40 a month. Each deal they sign with a customer will have multiple SKU's. For each product, they want to have NexTech technological advantage, they have to pay that price. Not sure if I posted the PR here, but they also signed a deal with a Medical Device Co the other day. Before NexTech, this company would have to drag a huge 1000 pound machine from place to place to give demonstrations. Now, they can use this Tech to give virtual demo's to buyers from a laptop, or Phone. This service cost $500 per month. Now, its possible to have (many) more sellers flying all around the world, pitching their product.

And if you listened to the 11 min clip I posted, this isnt even the big money maker NexTech has lined up. That's still coming. $$$

 

[KING WILL]

Tech moving up towards 14% today.

 

[KING WILL]

Up 10% this morning.



Good listening here, bout 30 mins long
Gets really good towards the end too.

Some wink wink stuff going on.



https://www.linkedin.com/in/sandrew

Hired this guy in Nov I believe to head up its Hollywood division.

Check out this guys history. I think were on to something thing here.

For more, google NexTech. AR SOLUTIONS Hollywood.

 

[broller]

Up 10% this morning.



Good listening here, bout 30 mins long
Gets really good towards the end too.

Some wink wink stuff going on.



https://www.linkedin.com/in/sandrew

Hired this guy in Nov I believe to head up its Hollywood division.

Check out this guys history. I think were on to something thing here.

For more, google NexTech. AR SOLUTIONS Hollywood.

respek for the info breh

 

[KING WILL]

respek for the info breh

Yw.


Amrn short interest down 6%

Short Interest in Amarin Co. plc (NASDAQ:AMRN) Declines By 6.0%

 

[KING WILL]

Big Money finna roll in

Yahoo is now part of Verizon Media

 

[KING WILL]

Big Money finna roll in

Yahoo is now part of Verizon Media

Nextech up over 15% in Canada this morning.

 

[broller]

Nextech up over 15% in Canada this morning.

I finally bought into it today. Should have heeded your advice earlier when it was cheaper. But if this blows up as much as expected it won't matter too much.

 

[KING WILL]

I finally bought into it today. Should have heeded your advice earlier when it was cheaper. But if this blows up as much as expected it won't matter too much.

Yes sir. Still plenty room to run.

 

[KING WILL]

Forgot to add.


AMRN ran a new commercial Sunday after the game. I seen it again last night at work. Until the FDA signs off, it has to be unbranded, which means it cant use the brand name Vascepa.

It peaked so much interest after airing the site crashed.

Crazy.

 

[KING WILL]

I wonder if this was that wink wink stuff I alluded to in that last NexTech interview I posted.


NexTech AR Launches New VR V-Commerce Division

 

[KING WILL]

Came cross these guys the other day (CYDY):


CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab (PRO 140) as a once-weekly monotherapy for HIV-infected patients and, plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab (PRO 140) can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.






First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatin" data-reactid="11">First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatin

Second patient with stage 4 HER2+ metastatic breast cancer (MBC) shows 50 percent shrinkage in the primary tumor and no new signs of metastasis in the brain after treatment with leronlimab as a monotherapy" data-reactid="12">Second patient with stage 4 HER2+ metastatic breast cancer (MBC) shows 50 percent shrinkage in the primary tumor and no new signs of metastasis in the brain after treatment with leronlimab as a monotherapy.


Yahoo is now part of Verizon Media

 

[KING WILL]

NexTech went from the $1.34 to $2.30 in a liil over week. Now its back down to $2.05 after 2 big days in the red. Hopefully another day in the red will allow us to add more under $2.

AMRN Scripts up 3.44% from last week. Someone did the math and if Scripts continue to rise at 3.44% every week, well hit $1.4B in sales EOY. HUGE! And lets be honest, as AMRN ramp up its sales force and continue educating the public and even the medical community via TV/Internet Ads, growth of 3.44% for the rest of the year seems small imo.

And this is not taken into account EU sales during the last Q (possible Aug approval).

Also, the bits and pieces Im reading about the generics case are indicating that the generics pretty much blew their case a few days ago. Too add, as the generic company is trying to fight our patents, we have been awarded 2 more patents since the court case has started.

Just remember 1 more thing I came cross the other day....A new study has found that the harden plaque is a greater risk of adverse CVE, not the soft plaque like we previously thought. Not sure if yall remember the Evap results I posted, but the Primary Endpoint of that study was the reduction of soft plaque. This is interesting becuz at 9 months the study showed that Vascepa slowed the progression of soft plaque, but it actually reduced the hard plaque by 1%, which we now know is more important .

Its gonna be interesting to see what Vascepa does to plaque at 18 Months.

 

[KING WILL]

Not NexTech, but check out the power of AR:

 

[KING WILL]

Long, but great read.

NexTech AR Solutions (OTC: NEXCF) Emerging leader in $120 billion Augmented Reality mega-trend. “Unicorn Farm” with multiple shots on goal/targeting multi-billion dollar market opportunities. – Starwood Research


***

Analyst Note:

NEXCF stock has increased over 150% since we initiated coverage 11/6/2019, from $1.06 to a recent high of $2.54.

We are now raising our Upside Potential Target price for NEXCF to $20.00 for next 12 months. (Increasing from original $5.00 Upside Potential Target as originally published 11/6/2019).

Since our initial report, less than 3 months ago, NEXCF has delivered strong results with rapidly increasing revenues. However, our key impetus for increasing the upside target to $20.00, is NEXCF’s launch of three new AR initiatives – which we believe can be transformative for NEXCF’s revenues and valuation of the stock, over the next 12 months:

1) ARitize 3D-AR-360 Ad Network: 3D ads / “conversational 3D-AR shopping experience” – potential game changer for the $200 billion+ online ad industry.

2) Capture AR 3D app: Smartphone based app for 3D asset capture – breakthrough technology which massively reduces time and cost to capture 3D images. Essential for “mainstreaming” AR.

3) “V-Commerce”: Disruptive VR technology aiming at transforming $3.7 trillion retail sector by offering shoppers immersive product experiences.

NEXCF now boasts a unique combination of: multiple “Unicorn-potential” businesses – which are inside the emerging hot theme of Augmented Reality (Estimated to reach $120 billion in next 2 years, according to Statista).

(A “Unicorn” is the VC term for a start-up valued at $1 billion.)

Another key factor for raising the upside target to $20.00 is the confluence of technical/X-factors, which we see as one of the key drivers behind the wild price swings in the stock in recent days. As NEXCF gains increasing investor awareness, with the market starting to discover the AR theme – (Emerging $120 billion market according to Statista) – and NEXCF being the only “pure play” stock – with multiple (billion dollar potential) shots on goal. In some investor circles, NEXCF is apparently being viewed as the “micro-cap version of TSLA”